New: CLiMB liver-cancer trial results published in theNow in the Journal of Hepatology  Read →
Order Now →

For Investors & Media

Investor Relations

Recent press coverage and publications highlighting Helio Genomics’ market momentum — from nationwide HelioLiver availability through Quest Diagnostics to the CLiMB trial published in the Journal of Hepatology.

In the News

Press Coverage & Publications

Orange County Business Journal61.2K UVM

Helio Genomics Enters Full Launch with Quest Diagnostics

HelioLiver is now commercially available nationwide through Quest's 7,700 patient service centers. CEO Dr. Bharat Tewarie reveals two additional liver cancer tests in development — one to track treatment response, one to monitor recurrence after transplant — and notes Helio submitted its FDA premarket approval application in 2024.

Read the Coverage →
Yahoo! News44.5M UVM

Improving early detection and treatment of liver cancer

This syndicated GlobalData article examines how Helio's blood-based test detects tumor-associated epigenetic signals in cell-free DNA alongside protein biomarkers, noting five-year liver cancer survival drops from 37% for localized disease to just 3% for distant disease.

Read the Coverage →
FinanceWire102.2K UVM

Helio Genomics Announces New HelioLiver Access Through Quest

HelioLiver becomes available through Quest Diagnostics starting April 2026, combining cell-free DNA methylation patterns, protein biomarkers, and patient demographics through a proprietary AI algorithm. Testing remains centralized at Helio's CLIA-certified laboratory in West Lafayette, Indiana.

Read the Coverage →
GlobalData307.1K UVM

Improving early detection and treatment of liver cancer

Originally published by Pharmaceutical Technology, this analysis argues improved diagnostics could expand the population eligible for curative interventions, positioning the Quest partnership alongside Phase III perioperative immunotherapy trials such as IMbrave050 and CARES-009.

Read the Coverage →
Dealroom.co33K UVM

Quest Diagnostics to offer Helio Genomics' AI-powered liver cancer blood test across US network

The partnership makes HelioLiver widely available across the US from April 2026. The article highlights superior sensitivity to ultrasound for early-stage detection in high-risk individuals, noting liver cancer incidence has tripled since 1980 while 80–90% of eligible adults skip recommended ultrasounds.

Read the Coverage →
Precision Medicine Online156K UVM

Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for US

Helio is exploring AI-driven diagnostic opportunities beyond liver cancer while preparing HelioLiver for broader US availability, positioning its multi-analyte AI platform as a foundation for expanding into additional cancer types.

Read the Coverage →
Simply Wall St. News2.5M UVM

How Investors May Respond To Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening

Simply Wall St. analyzes how Quest's partnerships with Helio Genomics and Guardant Health could shape investor returns, with Quest's projected $11.9B revenue by 2028 dependent on growing higher-value preventive and oncology testing. The Helio partnership is described as 'additive to that story.'

Read the Coverage →
Scope Forward (Becker's GI & Endoscopy)17.7K UVM

Quest Diagnostics to offer liver cancer blood test

From April 2026, providers with a Quest account can order HelioLiver through Quest's network of approximately 7,700 patient service centers, integrated into existing provider workflows and EHR systems.

Read the Coverage →
LiverRight12.5K UVM

Helio Genomics and Quest Diagnostics

LiverRight emphasizes that liver cancer incidence has tripled and mortality doubled, yet 80–90% of at-risk patients don't get screened — and that blood-based liver cancer screening is 'moving toward mainstream clinical adoption at scale.'

Read the Coverage →
Becker's ASC Review609K UVM

Quest Diagnostics to offer liver cancer blood test

Becker's reports HelioLiver will be offered through Quest's nationwide provider network starting April 2026 — coverage subsequently syndicated by NewsBreak to 13.9 million readers.

Read the Coverage →
Brief Glance35K UVM

AI Blood Test for Liver Cancer Gains Massive Reach via Quest Deal

HelioLiver achieved 76% sensitivity for early-stage liver cancer in the CLiMB trial versus ultrasound's 47%, and identified 28.6% of tumors under 2cm where ultrasound detected none. The Quest partnership addresses the gap where 80–90% of eligible patients skip biannual ultrasounds.

Read the Coverage →
NewsBreak13.9M UVM

Quest Diagnostics to offer liver cancer blood test

NewsBreak syndicated the Becker's ASC Review announcement to its 13.9 million monthly visitors, amplifying the story from Becker's clinical audience to a mainstream national readership.

Read the Coverage →
SAHM Capital220.5K UVM

How Investors May Respond To Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening

SAHM Capital syndicates the Simply Wall St. analysis framing the Helio and Guardant partnerships as additive to Quest's growth narrative around higher-margin advanced oncology testing, with projected 2028 revenue of $11.9 billion.

Read the Coverage →

Stay Connected With Us

Subscribe to our newsletter for the latest updates on our journey to defeat cancer.

Subscribe → Discover HelioLiver LDT →
Discover HelioLiver →